HIV-1 genetic variation and drug resistance development

A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure

(2013) Anne-Geneviève Marcelin et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations Associated with First-Line Stavudine-Containing Antiretroviral Therapy: Programmatic Implications for Countries Phasing Out Stavudine

(2013) Michele W. Tang et al.   JOURNAL OF INFECTIOUS DISEASES

Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens

(2013) Gert U. Van Zyl et al.   PLoS One

High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen

(2012) Henry Sunpath et al.   AIDS

Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy

(2012) Maria Mercedes Santoro et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Effect of HIV Type 1 Subtype on Virological and Immunological Response to Combination Antiretroviral Therapy: Evidence for a More Rapid Viral Suppression for Subtype A Than Subtype B-Infected Greek Individuals

(2012) Dimirios Paraskevis et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Effect of Natural Polymorphisms in the HIV-1 CRF02_AG Protease on Protease Inhibitor Hypersusceptibility

(2012) André F. A. Santos et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir

(2012) K. Theys et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Preexisting mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virologic response

(2012) Johan Vingerhoets et al.   ANTIVIRAL THERAPY

HIV-1 Subtype and Virological Response to Antiretroviral Therapy: A Confirmatory Analysis

(2012) David I. Dolling et al.   CLINICAL INFECTIOUS DISEASES

Simian retroviruses in African apes

(2012) M. Peeters et al.   CLINICAL MICROBIOLOGY AND INFECTION

The Evolution of Drug Resistance Interpretation Algorithms: ANRS, REGA and Extension of Resistance Analysis to HIV-1 Group O and HIV-2

(2012) Josef Eberle et al.   INTERVIROLOGY

Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients

(2012) Calvin J. Cohen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Raltegravir-Based Regimens Are Effective in HIV-1 Group O–Infected Patients

(2012) Agnès Depatureaux et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Evaluating Immunologic Response and Clinical Deterioration in Treatment-Naive Patients Initiating First-Line Therapies Infected With HIV–1 CRF01_AE and Subtype B

(2012) Rebecca A. Oyomopito et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors

(2012) J. L. Martinez-Cajas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G

(2012) A. C. Palma et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

HIV-1 Phenotypic Reverse Transcriptase Inhibitor Drug Resistance Test Interpretation Is Not Dependent on the Subtype of the Virus Backbone

(2012) Michelle Bronze et al.   PLoS One

Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies

(2011) Jürgen K. Rockstroh et al.   AIDS

Global trends in molecular epidemiology of HIV-1 during 2000–2007

(2011) Joris Hemelaar et al.   AIDS

Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients – Impact of HIV subtypes and prior raltegravir experience

(2011) Carolina Garrido et al.   ANTIVIRAL RESEARCH

Improved Virological Outcome in White Patients Infected With HIV-1 Non-B Subtypes Compared to Subtype B

(2011) A. U. Scherrer et al.   CLINICAL INFECTIOUS DISEASES

Impact of HIV-1 Group O Genetic Diversity on Genotypic Resistance Interpretation by Algorithms Designed for HIV-1 Group M

(2011) Agnès Depatureaux et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies

(2011) Laurence Rimsky et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype

(2011) I. Malet et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

(2011) P. K. Quashie et al.   JOURNAL OF VIROLOGY

The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes

(2011) Saleta Sierra et al.   MEDICAL MICROBIOLOGY AND IMMUNOLOGY

A Template-Dependent Dislocation Mechanism Potentiates K65R Reverse Transcriptase Mutation Development in Subtype C Variants of HIV-1

(2011) Dimitrios Coutsinos et al.   PLoS One

Polymorphism in Gag Gene Cleavage Sites of HIV-1 Non-B Subtype and Virological Outcome of a First-Line Lopinavir/Ritonavir Single Drug Regimen

(2011) Jade Ghosn et al.   PLoS One

Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen

(2010) Charlotte Charpentier et al.   AIDS

Full-length HIV-1 Gag determines protease inhibitor susceptibility within in-vitro assays

(2010) Ravindra K Gupta et al.   AIDS

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies

(2010) Johan Vingerhoets et al.   AIDS

Natural Polymorphisms of integrase Among HIV Type 1-Infected South African Patients

(2010) Muhammad Q. Fish et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Short Communication: Activity of Etravirine on Different HIV Type 1 Subtypes: In Vitro Susceptibility in Treatment-Naive Patients and Week 48 Pooled DUET Study Data

(2010) Johan Vingerhoets et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

HIV-1 Protease Codon 36 Polymorphisms and Differential Development of Resistance to Nelfinavir, Lopinavir, and Atazanavir in Different HIV-1 Subtypes

(2010) I. Lisovsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Baseline Genotypic and Phenotypic Susceptibilities of HIV-1 Group O to Enfuvirtide

(2010) A. Depatureaux et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Distinct Mutation Pathways of Non-Subtype B HIV-1 during In Vitro Resistance Selection with Nonnucleoside Reverse Transcriptase Inhibitors

(2010) M.-T. Lai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Combination of V106I and V179D Polymorphic Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Resistance to Efavirenz and Nevirapine but Not Etravirine

(2010) H. Gatanaga et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients

(2010) Inge Dierynck et al.   ANTIVIRAL THERAPY

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens

(2010) D. da Silva et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection

(2010) David A. Cooper et al.   JOURNAL OF INFECTIOUS DISEASES

HIV Genetic Diversity and Drug Resistance

(2010) André F. Santos et al.   Viruses-Basel

Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes

(2009) Eva Poveda et al.   AIDS

Integrase polymorphism and HIV-1 group O diversity

(2009) Marie Leoz et al.   AIDS

Raltegravir and Etravirine Are Active against HIV Type 1 Group O

(2009) Verónica Briz et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

(2009) H. Azijn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Resistance-Associated Mutations to Etravirine (TMC-125) in Antiretroviral-Naive Patients Infected with Non-B HIV-1 Subtypes

(2009) A. I. Maiga et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of HIV‐1 Subtype on Virologic and Immunologic Response to Starting Highly Active Antiretroviral Therapy

(2009) Anna Maria Geretti et al.   CLINICAL INFECTIOUS DISEASES

Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G

(2009) Ana Carolina Palma et al.   INFECTION GENETICS AND EVOLUTION

Impact of Amino Acid Variations in Gag and Protease of HIV Type 1 CRF01_AE Strains on Drug Susceptibility of Virus to Protease Inhibitors

(2009) Piyamat Jinnopat et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G

(2009) A. F. Santos et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection

(2009) C. Garrido et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Signature Nucleotide Polymorphisms at Positions 64 and 65 in Reverse Transcriptase Favor the Selection of the K65R Resistance Mutation in HIV‐1 Subtype C

(2009) Cédric F. Invernizzi et al.   JOURNAL OF INFECTIOUS DISEASES

Drug Resistance Mutation Profile and Accumulation Kinetics in Human Immunodeficiency Virus-Positive Individuals Infected with Subtypes B and F Failing Highly Active Antiretroviral Therapy Are Influenced by Different Viral Codon Usage Patterns

(2008) A. Waleria-Aleixo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure☆

(2008) A DUMANS et al.   INFECTION GENETICS AND EVOLUTION